证券代码：300143 证券简称：盈康生命 公告编号：2025-041 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 盈康生命科技股份有限公司 关于使用闲置自有资金进行现金管理的公告 1、投资种类：安全性高、流动性好、低风险的存款类产品； 2、投资金额：不超过人民币3亿元的闲置自有资金； 3、特别风险提示：公司本次现金管理所投资的产品是银行等金融机构发行 的流动性好、安全性高的产品，具有投资风险低、本金安全度高的特点。鉴于 金融市场的复杂性及多因素影响，本次投资可能因市场剧烈波动而面临不利影 响风险。敬请投资者注意投资风险。 盈康生命科技股份有限公司（以下简称"公司"）于2025年8月22日召开的 第六届董事会第二十次会议，审议通过了《关于使用闲置自有资金进行现金管 理的议案》，同意公司及子公司在确保资金安全且不影响正常经营发展资金需求 的前提下，使用不超过人民币3亿元（含本数，下同）的闲置自有资金用于购买 安全性高、流动性好、低风险的存款类产品，使用期限自董事会审议通过之日 起12个月内有效。在上述投资额度和期限范围内，资金可以循环滚动使用 ...

| 非经营性资 | | 占用方与上 | 上市公司核 | 2025 年期初 | 2025 年 1-6 | 月占 | 2025 年 月占 1-6 | 2025 年 月偿 1-6 | 2025 年 6 月 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 金占用 | 资金占用方名称 | 市公司的关 | 算的会计科 | 占用资金余 | 用累计发生金额 | | 用资金的 | 还累计发 | 30日占用资 | 原因 | 占用性质 | | | | 联关系 | 目 | 额 | （不含利息） | | 利息 | 生金额 | 金余额 | | | | 现大股东及其 | | | | | | | | | | | | | 附属企业 | | | | | | | | | - | | | | 小计 | | | | - | - | | | - | - | | | | 原大股东及其 | | | | | | | | | | | | | 附属企业 | | | | | | | | | - | | | | 小计 | | | | - | ...

证券代码：300143 证券简称：盈康生命 公告编号：2025-040 盈康生命科技股份有限公司 关于 2025 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 盈康生命科技股份有限公司（以下简称"公司"）董事会根据中国证券监督 管理委员会颁布的《上市公司募集资金监管规则》和深圳证券交易所发布的《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有 关规定，编制了公司 2025 年半年度募集资金存放与使用情况的专项报告。报告主 要内容如下： 一、募集资金基本情况 （一）2020年度非公开发行股票募集资金基本情况 1、募集资金金额及到位时间 经中国证券监督管理委员会《关于核准盈康生命科技股份有限公司非公开发 行股票的批复》（证监许可[2020]1030号）核准，公司向特定对象青岛盈康医疗投 资有限公司非公开发行人民币普通股（A股）96,312,746股，每股面值为人民币1 元，每股发行价格为人民币7.61元。本次发行募集资金总额为人民币732,939,997.06 元，扣除各项发行费用（不含税） ...

证券代码：300143 证券简称：盈康生命 公告编号：2025-038 盈康生命科技股份有限公司 第六届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 （一）审议通过《关于公司<2025 年半年度报告>及其摘要的议案》 董事会审议了公司《2025 年半年度报告全文》及《2025 年半年度报告摘要》， 董事会全体成员一致认为公司《2025 年半年度报告》真实、准确、完整地反映了公 司 2025 年半年度的财务状况和经营成果，不存在虚假记载、误导性陈述和重大遗 漏，披露的信息真实、准确、完整。 1 具体内容详见公司同日于巨潮资讯网（http://www.cninfo.com.cn）披露的《2025 年半年度报告全文》及《2025 年半年度报告摘要》。《2025 年半年度报告摘要》 同时刊登在《证券时报》《证券日报》《中国证券报》《上海证券报》。 本议案已经公司第六届董事会审计委员会第十五次会议审议通过，并同意提交 公司董事会审议。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 （二）审议通过《关于公司 2 ...

Financial Performance - The company's operating revenue for the first half of 2025 was ¥842,954,166.22, representing a 2.40% increase compared to ¥823,222,466.04 in the same period last year[22]. - The net profit attributable to shareholders was ¥61,827,220.33, up 12.82% from ¥54,801,148.25 in the previous year[22]. - The net profit after deducting non-recurring gains and losses increased by 19.22%, reaching ¥60,589,892.34 compared to ¥50,822,557.54 in the same period last year[22]. - The net cash flow from operating activities decreased by 32.31% to ¥148,623,194.00, down from ¥219,567,034.58 in the previous year[22]. - Total assets at the end of the reporting period were ¥4,150,991,620.76, a 17.37% increase from ¥3,536,733,888.57 at the end of the previous year[22]. - The net assets attributable to shareholders increased by 2.74% to ¥2,497,166,188.52 from ¥2,430,580,107.07 at the end of the previous year[22]. - Basic earnings per share decreased by 3.26% to ¥0.0832 from ¥0.0860 in the same period last year[22]. - Diluted earnings per share also decreased by 3.37% to ¥0.0831 from ¥0.0860 in the previous year[22]. - The weighted average return on net assets was 2.51%, down from 3.95% in the same period last year, a decrease of 1.44%[22]. - The company plans not to distribute cash dividends or issue bonus shares[5]. Revenue and Growth - The company achieved operating revenue of 842.95 million yuan, a year-on-year increase of 2.4%, and a net profit attributable to shareholders of 61.83 million yuan, up 12.8% year-on-year[31]. - The gross profit margin improved by 0.5 percentage points, while the expense ratio decreased by 2 percentage points[31]. - Revenue from the oncology service segment reached 214.95 million yuan, representing a year-on-year growth of 25.14%[35]. - The number of oncology outpatient visits at Friendship Hospital increased by 21.59% to 24,218 visits, and the proportion of level IV surgeries rose by 8 percentage points[35]. Acquisitions and Investments - The company acquired Changsha Kexin Hospital, enhancing its medical center layout in the Central China region[36]. - The company completed the transfer of 51% equity in Changsha Kexin Hospital, which is now a subsidiary included in the consolidated financial statements[74]. - The company acquired a 51% stake in Changsha Kexin Tumor Hospital for CNY 357,000,000.00, with the equity transfer registration expected to be completed by May 30, 2025[100]. - The acquisition of Changsha Kexin Oncology Hospital is expected to enhance the company's capabilities and service offerings[131]. Research and Development - Research and development investment decreased by 15.08% to ¥21,280,083.46 from ¥25,057,697.42, indicating a focus on optimizing R&D processes[86]. - The company established partnerships with renowned institutions to enhance R&D capabilities, focusing on AI applications in medical devices[81]. - The company has implemented an AI strategy since 2021, becoming a pioneer in AI deployment within the healthcare sector[80]. - AI applications are being utilized across eight major scenarios in the company's hospitals, improving patient experience and service efficiency[80]. Medical Device Innovations - The company has implemented over 100 innovative applications and solutions to enhance clinical diagnosis and treatment levels across various departments, including neurology and orthopedics[38]. - The company’s infusion pump market share in China exceeded 10%, ranking third, while the breast molybdenum target device also held a 10% market share, maintaining third place[44]. - Overseas medical device revenue increased by 35% year-on-year, driven by a user-centric strategy and localized team deployment[46]. - The company is focusing on enhancing its product offerings in the field of imaging and monitoring, with several devices aimed at improving patient care and operational efficiency[61]. Financial Management - The company reported a significant increase in financing cash flow by 352.19% to ¥170,484,657.91, mainly due to increased borrowings[86]. - The company has ongoing investments in the Haier Health Medical Device Smart Industrial Park, with an investment of CNY 10,457,917.46 during the reporting period[103]. - The company reported a total of CNY 511,000,000.00 in purchases and CNY 401,924,945.47 in sales of financial assets during the reporting period[95]. - The company plans to use the raised funds for group financing projects, with 98.33% of the funds already utilized[108]. Market Strategy - The company plans to expand its product layout focusing on tumor prevention, diagnosis, treatment, and family health management to mitigate overseas market dependency[125]. - The company is preparing for potential policy changes in the healthcare industry to enhance its risk resilience[126]. - The company is actively exploring AI applications in healthcare, aiming to enhance its competitive advantage in the "AI + healthcare" sector[128]. - The company is committed to continuous innovation in AI health management, anticipating significant improvements in various aspects of its operations[128]. Corporate Governance - The company appointed Ma Anjie as the new general manager following the resignation of the previous general manager and vice general manager[177]. - The company has established a "Value Management System" to enhance development quality and investor returns, approved on April 25, 2025[132]. - The "Quality and Return Dual Improvement" action plan was disclosed on January 15, 2025, focusing on core competencies in oncology and enhancing shareholder returns[133]. Shareholder Information - The total number of shares after the recent changes is 749,451,604, maintaining a 100% shareholding ratio[186]. - The largest shareholder, Qingdao Yinkang Medical Investment Co., Ltd., holds 49.61% of shares, totaling 371,782,549[191]. - The number of shareholders at the end of the reporting period is 18,298[191]. - The company has not disclosed any plans for share repurchase or issuance in the recent report[190].

Core Viewpoint - 盈康生命 reported a solid performance in the first half of the year, achieving revenue growth and net profit increase, indicating a trend of high-quality development in the company. Financial Performance - The company achieved operating revenue of 843 million yuan, a year-on-year increase of 2.4% [1] - Net profit attributable to shareholders reached 61.83 million yuan, up 12.8% year-on-year [1] - Deducting non-recurring gains and losses, the net profit was 60.59 million yuan, reflecting a year-on-year growth of 19.2% [1] - Gross margin improved by 0.5 percentage points, while expense ratio decreased by 2 percentage points, showcasing operational efficiency [1] Medical Services Development - The core business in medical services generated revenue of 653 million yuan, a year-on-year increase of 2.28% [2] - Revenue from oncology services reached 215 million yuan, growing by 25.14% year-on-year, with significant increases in patient visits and advanced surgical procedures [2] - The company has established a comprehensive service system covering early screening, diagnosis, mid-to-late stage treatment, and rehabilitation management [2] Strategic Expansion - The company expanded its regional presence by acquiring Changsha Kexin Tumor Hospital, enhancing its capabilities in minimally invasive tumor treatment [2] - The acquisition is expected to enrich the company's oncology pre-diagnosis and treatment ecosystem, providing additional growth momentum [2] Innovative Service Offerings - The company is focused on integrating medicine with new technologies and experiences to meet diverse health needs [3] - New services include weight loss, precision anti-aging, and international medical services, alongside the introduction of over 100 new clinical technologies [3] - The company has pioneered brain-machine interface applications in healthcare, achieving notable surgical outcomes in Parkinson's treatment [3] AI Integration and Efficiency - The company has implemented a "medical + AI" strategy, leading to significant improvements in service capacity and operational efficiency [4] - Key metrics include a 10% increase in per capita service volume and a 2 percentage point reduction in overall expense ratio [4] - AI technologies have reduced surgical complications by 10% and improved various operational efficiencies, including a 66% increase in imaging diagnosis efficiency [4] Market Growth in Medical Devices - The company achieved a 35% year-on-year growth in overseas medical device revenue, driven by strategic market expansion [5] - In the domestic market, the company has upgraded its products and channels, achieving over 40% coverage in top-tier hospitals [5] - The company’s infusion pumps and mammography equipment have gained significant market share, ranking third in their respective categories [5] Global Market Strategy - The company employs a "one country, one policy" strategy for overseas market expansion, enhancing user experience and product application [6] - New partnerships with nine overseas distributors have been established, expanding coverage across multiple global regions [6]

Core Viewpoint - Yingkang Life emphasizes its commitment to cutting-edge technology and innovative business models, indicating a strategic focus on enhancing core competitiveness and improving industry ecosystem layout through potential collaborations and investment opportunities [1] Summary by Relevant Categories Company Strategy - The company is focused on evaluating and exploring various potential collaborations and investment opportunities that align with its strategic development plan [1] Innovation and Technology - Yingkang Life maintains a strong interest in frontier technologies and innovative business models, which are crucial for its growth and competitiveness in the industry [1] Communication and Disclosure - The company assures that it will timely disclose any developments that meet information disclosure standards, reflecting its commitment to transparency with investors [1]

Group 1 - The high-pressure oxygen chamber concept sector experienced a decline of 0.76%, ranking among the top declines in concept sectors as of the market close on August 22 [1] - Within the sector, major declines were observed in companies such as Samsung Medical, Aoyang Health, and Dahu Co., with notable increases in Hangyang Co., Yinkang Life, and International Medicine, which rose by 0.97%, 0.86%, and 0.37% respectively [1] Group 2 - The high-pressure oxygen chamber concept sector saw a net outflow of 260 million yuan in principal funds today, with six stocks experiencing net outflows [2] - The stock with the highest net outflow was Tiedao Heavy Industry, which had a net outflow of 143 million yuan, followed by Innovative Medical, Samsung Medical, and Aoyang Health with net outflows of 60.83 million yuan, 43.65 million yuan, and 13.12 million yuan respectively [2] - Conversely, the stocks with the highest net inflows included International Medicine, Jinling Pharmaceutical, and Yinkang Life, with net inflows of 3.35 million yuan, 3.27 million yuan, and 3.20 million yuan respectively [2]

Group 1 - The high-pressure oxygen chamber concept declined by 0.68%, ranking among the top declines in concept sectors as of the market close on August 20 [1] - Within the high-pressure oxygen chamber sector, companies such as Innovate Medical, Yinkang Life, and Aoyang Health experienced significant declines, while Iron Construction Heavy Industry, Samsung Medical, and Dahu Co. saw increases of 4.29%, 1.08%, and 0.89% respectively [1] - The high-pressure oxygen chamber sector experienced a net outflow of 444 million yuan in main funds, with Innovate Medical leading the outflow at 537 million yuan [2] Group 2 - The top gainers in the market included the Tonghuashun Fruit Index at 3.70%, AI mobile phones at 2.77%, and MCU chips at 2.60%, while the high-pressure oxygen chamber concept was among the top decliners [2] - The main funds saw significant outflows from several stocks in the high-pressure oxygen chamber sector, with Innovate Medical, Aoyang Health, and Dahu Co. being the most affected [2] - Conversely, Iron Construction Heavy Industry, Samsung Medical, and Jinling Pharmaceutical attracted net inflows of main funds, indicating a shift in investor interest [2]

Summary of Key Points Core Viewpoint - The 2024 A-share Secretary Data Report indicates that the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan, highlighting the significant role of secretaries in connecting investors and listed companies [1][2]. Group 1: Overall Salary and Demographics - The total salary for A-share listed company secretaries in 2024 is 4.086 billion yuan, with an average annual salary of 754,300 yuan [1]. - Among the secretaries, those aged 40 and below constitute 43% of the market, while those aged 50 and above account for 22% [1]. - The educational background of secretaries shows that 34% hold a bachelor's degree, 52% have a master's degree, and 14% possess a doctoral degree [1]. Group 2: Industry-Specific Salary Insights - The average annual salary for secretaries in the pharmaceutical and medical service sector is 839,200 yuan [2]. - The distribution of salaries shows that 24% earn below 500,000 yuan, 48% earn between 500,000 and 1 million yuan, and 28% earn above 1 million yuan [2]. - The top three highest-paid secretaries are Gilbert Shing Chung Li from Kanglong Chemical with 1.9855 million yuan, Gao Dapeng from Zhaoyan New Drug with 1.7384 million yuan, and Xu Xiangke from Kailaiying with 1.6114 million yuan [2].